Baxter International
Illinois, United States · Biotechnology, Health Care, Manufacturing
Baxter International Inc. is a global medtech leader, with a leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices, and other sites of care.
Key facts
- Headquarters
- Illinois, United States
- Employees
- 40,498
- Industries
- Biotechnology, Health Care, Manufacturing
- Status
- Public (BAX)
- Website
- baxter.com
- Company page
Recent activity at Baxter International
- : Baxter Appoints John Rogers as Chief Financial Officer
- : SEC 8-K (5.02): On August 18, 2026, Baxter International Inc. appointed John Rogers as Executive Vice President and Chief Financial Officer (CFO), effective October 1, 2026. Mr. Rogers, previously CFO at Smith+Nephew plc and with extensive experience in senior financial roles at WPP plc and J Sainsbury plc, will receive a target annual base salary of $925,000 along with a 100% bonus opportunity tied to his base salary. The agreement includes significant equity participation, where he will receive a total target grant value of $4,000,000 in annual equity, and additional off-cycle equity grants to compensate for his previous employer's unvested awards, post-Transition Date. This strategic hire is aimed at fortifying Baxter's financial leadership as the company continues its operational growth.
- : SEC 8-K (1.01): On August 18, 2026, Baxter International Inc. entered into Amendment No. 2 to its existing five-year credit agreement originally dated June 11, 2025. This agreement involves Baxter Healthcare SA and Baxter World Trade SRL as borrowers, and JPMorgan Chase Bank, N.A. acts as the Administrative Agent. Amendment No. 2 modifies terms agreed upon previously, which had first been amended on November 25, 2025. The strategic intent behind this amendment is not detailed, but it typically indicates adjustments to financial provisions that could impact the company's liquidity and business operations moving forward.
- : SEC 8-K (5.02):
- : SEC 8-K (8.01): On August 4, 2026, Baxter International Inc. announced the commencement of cash tender offers to purchase up to $500 million in aggregate for various series of the Company’s outstanding Senior Notes. The Offers include the 3.132% Senior Notes due 2051, 3.500% Senior Notes due 2046, 4.500% Senior Notes due 2043, and 2.539% Senior Notes due 2032. The tender offers are to be conducted under the terms set forth in the Company’s offer to purchase dated the same day, and it is important to note that the Offers are not being made in jurisdictions where compliance would violate local laws. This activity is significant as it reflects the Company’s strategy to manage its debt portfolio effectively.
- : SEC 8-K (8.01): On August 4, 2026, Baxter International Inc. announced the commencement of cash tender offers to purchase up to $500 million in aggregate purchase price of several series of its outstanding Senior Notes, specifically targeting the 3.132% Senior Notes due 2051, 3.500% Senior Notes due 2046, 4.500% Senior Notes due 2043, and 2.539% Senior Notes due 2032. This transaction aims to manage the company's debt portfolio by providing liquidity and potentially reducing interest costs. The Offers are subject to specific terms and conditions outlined in the company's detailed offer to purchase. This strategic move indicates Baxter's proactive approach in optimizing its capital structure.
- : SEC 8-K (8.01): On July 29, 2026, the Company's Board of Directors declared a quarterly cash dividend of $0.01 per share of common stock. This announcement is part of their regular dividend policy and signifies their commitment to returning value to shareholders. The dividend is scheduled to be paid on October 1, 2026, to stockholders of record as of August 28, 2026. This action may improve shareholder satisfaction and could positively influence the stock price leading up to the dividend payment date.
- : SEC 8-K (7.01):
- : SEC 8-K (5.02):
- : SEC 8-K (8.01): On April 29, 2026, Baxter International Inc.'s Board of Directors declared a quarterly cash dividend of $0.01 per share of common stock. This dividend is scheduled for payment on July 1, 2026, to stockholders of record by May 29, 2026. This action marks an ongoing commitment to returning value to shareholders and may reflect the company's continued financial health despite economic conditions.
Leadership
- John Rogers, Chief Financial Officer
- Anita Zielinski, Chief Financial Officer
- Vaibhav Sethi, Chief Technology Officer
- Cansu Demirli, Chief Operating Officer
- Windy How, Chief Financial Officer
- Anshita Singh, Human Resources Business Partner
- Aparna Gupta, Senior Manager Hr
- Neha Basera, Manager, Hr
- Bob Probst, VP Finance
- Melissa Kincade, Director of Finance
- Ilana Shifrin, Head of Finance
- Jim C., Retired It Professional
Verified email and direct lines for Baxter International’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Baxter International files 22 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Baxter International in the news
- Baxter Showcases Recent Innovations at AORN Global Surgical Conference and Expo 2026 - Baxter (Apr 13, 2026)
- ShinyHunters Leaks 7.1 Million Baxter International Records - The HIPAA Journal (Aug 26, 2026)
- Baxter annual profit forecast disappoints as key product troubles mount - Reuters (Feb 12, 2026)
- Recalls issued for possible fiberglass particles in IV solutions made at WNC facility: FDA - WLOS (Sep 03, 2026)
- Healthcare company recalls multiple injectables. See affected drugs - USA Today (Aug 27, 2026)
- Smart Money is Buying Baxter International Inc. (BAX) - The Acquirer's Multiple (Apr 20, 2026)
- Baxter cuts roughly 90 jobs at IV solutions plant that recovered from Hurricane Helene - MedTech Dive (Feb 10, 2026)
- Baxter Releases Inaugural Connected Hospital Report - Business Wire (Sep 30, 2026)
Companies similar to Baxter International
- Boston Scientific · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- IEC Medical Systems · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Becton Dickinson · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Alcon Silver · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Mindray · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
About Baxter International: questions and answers
What does Baxter International do?
Baxter International Inc. is a global medtech leader, with a leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices, and other sites of care.
Where is Baxter International headquartered?
Baxter International is headquartered in Illinois, United States.
How many employees does Baxter International have?
Baxter International has about 40,498 employees.
What is the latest news on Baxter International?
On Aug 19, 2026, Baxter Appoints John Rogers as Chief Financial Officer
Is Baxter International a public company?
Yes. Baxter International is publicly traded under the ticker BAX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy